Navigation Links
Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
Date:7/24/2012

SAN DIEGO, July 24, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the appointment of Dr. Stephen Newman to its Board of Directors.  Dr. Newman is the former Vice Chairman and Chief Operating Officer of Tenet Healthcare Corporation (THC), a health care delivery and services company, until his retirement in June 2012.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"Dr. Newman's extensive leadership and experience, ranging from medical practitioner to COO of a major health care delivery system operating several dozen hospitals and providing services to hundreds of institutions, brings tremendous insight and value to Optimer's Board, particularly in these early stages of introducing DIFICID to the health care system," said Pedro Lichtinger, President and CEO of Optimer.

Dr. Newman, 62, most recently served as Vice Chairman and Chief Operating Officer of Tenet Healthcare Corporation until his retirement in June 2012. Dr. Newman joined Tenet in February 1999 and held various positions of increasing responsibility before eventually becoming COO, including Chief Executive Officer for Tenet's California region. Before joining Tenet, Dr. Newman held executive positions at Columbia/HCA Inc. from April 1997 to February 1999 and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans from August 1990 to March 1997. Prior to 1990, Dr. Newman served as Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine and as Director of Gastroenterology and Nutrition Support at Children's Medical Center in Dayton, Ohio.  Dr. Newman recently completed a five-year term on the Board of Directors of the Federation of American Hospitals and presently serves on the Federal Reserve Bank of Atlanta's Labor Education and Healthcare Advisory Committee. Dr. Newman holds a bachelor's degree from Rutgers University, an M.B.A. from Tulane University and a medical degree from the University of Tennessee. He completed his internship, residency and fellowship at Emory University School of Medicine. Dr. Newman also completed the Advanced Management Program at the University of Pennsylvania's Wharton School of Business.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem.  Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-964-3418

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
2. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
5. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
6. MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results
7. Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012
8. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
9. Webcast Alert: Isis Pharmaceuticals Second Quarter 2012 Financial Results Conference Call
10. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... 29, 2017 , ... Sterling Global Products is pleased to ... biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs manufactured by this ... Texas, operates more than 350 stores throughout Texas and expanding into northern Mexico ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Beginning in 2017, Ridgecrest Herbals ... This begins with the popular ClearLungs Extra Strength formula. To ensure that the effectiveness ... in the following ways:, , Removal of the homeopathic element ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: April ... “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on her ... Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she was ...
(Date:4/28/2017)... ... 2017 , ... Children and adolescents who enter the foster ... in the general population. That’s because foster care is designed to protect children ... no fault of their own, youth who have experienced trauma often have difficulty ...
Breaking Medicine News(10 mins):